[go: up one dir, main page]

PT934061E - Isobutilgaba e seus derivados para o tratamento da dor - Google Patents

Isobutilgaba e seus derivados para o tratamento da dor

Info

Publication number
PT934061E
PT934061E PT97932617T PT97932617T PT934061E PT 934061 E PT934061 E PT 934061E PT 97932617 T PT97932617 T PT 97932617T PT 97932617 T PT97932617 T PT 97932617T PT 934061 E PT934061 E PT 934061E
Authority
PT
Portugal
Prior art keywords
pain
isobutilgaba
derivatives
treatment
gamma
Prior art date
Application number
PT97932617T
Other languages
English (en)
Inventor
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT934061(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PT934061E publication Critical patent/PT934061E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97932617T 1996-07-24 1997-07-16 Isobutilgaba e seus derivados para o tratamento da dor PT934061E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2233796P 1996-07-24 1996-07-24

Publications (1)

Publication Number Publication Date
PT934061E true PT934061E (pt) 2003-10-31

Family

ID=21809080

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97932617T PT934061E (pt) 1996-07-24 1997-07-16 Isobutilgaba e seus derivados para o tratamento da dor

Country Status (24)

Country Link
US (2) USRE41920E1 (pt)
EP (1) EP0934061B3 (pt)
JP (1) JP3693258B2 (pt)
KR (1) KR100491282B1 (pt)
CN (1) CN1094757C (pt)
AT (1) ATE241351T1 (pt)
AU (1) AU714980B2 (pt)
BR (1) BR9710536A (pt)
CA (1) CA2255652C (pt)
CU (1) CU22850A3 (pt)
DE (1) DE69722426T3 (pt)
DK (1) DK0934061T6 (pt)
ES (1) ES2200184T7 (pt)
HK (1) HK1021134A1 (pt)
HR (1) HRP970387A2 (pt)
HU (2) HU228426B1 (pt)
IL (1) IL126999A (pt)
NO (2) NO325822B1 (pt)
NZ (1) NZ332762A (pt)
PL (1) PL189872B1 (pt)
PT (1) PT934061E (pt)
SI (1) SI0934061T1 (pt)
WO (1) WO1998003167A1 (pt)
ZA (1) ZA976562B (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
BR9812162A (pt) * 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
IL139298A0 (en) * 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
WO2000002547A2 (en) * 1998-07-09 2000-01-20 Warner-Lambert Company The treatment of renal colic with gaba analogs
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
US20030045500A1 (en) * 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
EP1093366B1 (en) * 1998-07-09 2004-10-13 Warner-Lambert Company LLC Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles
CA2332927A1 (en) * 1998-07-09 2000-01-20 Catherine A. Segal Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
EP1840117A1 (en) * 1999-06-10 2007-10-03 Warner-Lambert Company LLC Mono- and disubstituted 3-propyl gamma-aminobutyric acids
SK287247B6 (sk) * 1999-06-10 2010-04-07 Warner-Lambert Company Llc Kyselina (3S,5R)-3-aminometyl-5-metyloktánová, jej použitie na výrobu liečiva a farmaceutický prostriedok s jej obsahom
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
CN1210253C (zh) * 2000-01-27 2005-07-13 沃尼尔·朗伯公司 不对称合成(s)－(+)－3－(氨甲基)－5－甲基己酸
US6687187B2 (en) * 2000-08-11 2004-02-03 Phonak Ag Method for directional location and locating system
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
HUP0400183A2 (hu) * 2001-06-11 2004-07-28 Xenoport Inc. Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR100890875B1 (ko) 2001-09-03 2009-03-31 뉴론 파마슈티칼즈 에스. 피. 에이. 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2509615A1 (en) * 2002-12-13 2004-07-01 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
JP2006511604A (ja) * 2002-12-13 2006-04-06 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体
EP1572188A1 (en) * 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
CA2538802C (en) * 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
CA2545543A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
BRPI0508615A (pt) * 2004-03-12 2007-07-31 Warner Lambert Co lingandos de bisfosfina c1-simétrica e seu emprego na sìntese assimétrica de pregabalina
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
BRPI0508998A (pt) * 2004-04-01 2007-09-04 Warner Lambert Co preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
GEP20104895B (en) * 2004-06-21 2010-02-25 Warner Lambert Co Preparation of pregabalin and related compounds
NZ552651A (en) * 2004-08-27 2010-07-30 Sanol Arznei Schwarz Gmbh Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
NZ554737A (en) * 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
US7763749B2 (en) * 2005-05-10 2010-07-27 Teva Pharmaceutical Industries Ltd. Method for the preparation of Pregabalin and salts thereof
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
CN101180045A (zh) * 2005-05-20 2008-05-14 辉瑞有限公司 非甾类抗炎药物与α-2-δ配体的协同组合
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
ES2398579T3 (es) 2005-09-19 2013-03-20 Teva Pharmaceutical Industries Ltd Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico
US7462738B2 (en) * 2006-05-24 2008-12-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
CA2651679C (en) 2006-06-15 2017-01-03 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
BRPI0803092A2 (pt) * 2007-03-22 2011-08-30 Teva Pharma sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina
KR20090101462A (ko) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
WO2009158343A1 (en) * 2008-06-23 2009-12-30 Teva Pharmaceutical Industries, Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010070593A2 (en) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Malonate esters
EP2400989B1 (en) 2009-02-24 2016-08-10 Nektar Therapeutics Gabapentin-peg conjugates
EA201101564A1 (ru) * 2009-05-15 2012-07-30 Редкс Фарма Лимитед Редокс производные лекарственных средств
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
EP2575798B1 (en) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
WO2012025861A1 (en) 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin
US9393205B2 (en) 2012-01-30 2016-07-19 Sun Pharmaceutical Industries Limited Gastroretentive tablets
EP2809303A1 (en) 2012-01-30 2014-12-10 Ranbaxy Laboratories Limited Pregabalin gr tablets
CN102966602B (zh) * 2012-12-14 2015-08-05 江苏海鸥冷却塔股份有限公司 一种冷却塔节能导流风筒
EP2946777B1 (en) 2013-01-18 2023-10-04 Kemphys Ltd. Medicine for treatment of neuropathic disease
PT2978748T (pt) 2013-03-27 2017-07-06 Pfizer Ireland Pharmaceuticals Processo e intermediários para a preparação de pregabalina
MA44212A (fr) 2015-05-26 2018-12-26 Isa Odidi Prégabaline à libération prolongée contrôlée
GB201617380D0 (en) 2016-10-13 2016-11-30 St George's Hospital Medical School Treatment for Osteoarthritis
KR102039344B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
KR102039345B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
GB201703123D0 (en) * 2017-02-27 2017-04-12 St George's Hospital Medical School Biomarkers
US20210221768A1 (en) 2018-05-14 2021-07-22 Xgene Pharmaceutical Inc. Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin
CN108926573A (zh) * 2018-07-03 2018-12-04 泓博元生命科技（深圳）有限公司 一种可降低尿酸指数的nadh组合物及其制备方法及应用
KR20200056719A (ko) 2018-11-15 2020-05-25 단국대학교 천안캠퍼스 산학협력단 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
WO2021191108A1 (en) 2020-03-23 2021-09-30 Plus Vitech, S.L. Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
WO2022038131A1 (en) 2020-08-19 2022-02-24 Plus Vitech, S.L. Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage
WO2022234110A1 (en) 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy
WO2022243430A1 (en) 2021-05-20 2022-11-24 Plus Vitech, S.L. Treatment of acne
WO2022253748A1 (en) 2021-06-03 2022-12-08 Plus Vitech, S.L. Combinations for the treatment of hpv

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
JPS4940460Y2 (pt) 1971-05-19 1974-11-06
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4123438A (en) 1975-03-05 1978-10-31 Stamicarbon, B.V. Process for preparing 2-pyrrolidones
NZ194348A (en) 1979-07-26 1982-09-14 Merrell Toraude & Co Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
US4322440A (en) 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
FI832935A (fi) 1982-08-20 1984-02-21 Midit Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
US4479005A (en) 1982-12-16 1984-10-23 The Dow Chemical Company Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
DE3476197D1 (en) 1983-08-01 1989-02-23 Mclean Hospital Corp Gaba esters and gaba analogue esters
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
DK170473B1 (da) 1985-06-20 1995-09-11 Daiichi Seiyaku Co S(-)-pyridobenzoxazinforbindelser
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
JP2535001B2 (ja) 1987-01-13 1996-09-18 ダイセル化学工業株式会社 Ｎ−アルキル化アミノ酸エステルの製法
JPH07116064B2 (ja) 1987-07-21 1995-12-13 三菱化学株式会社 分離剤
US4908210A (en) 1988-10-28 1990-03-13 Eastman Kodak Company Lactylic salt tablet formulations and tablets
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
GB8921304D0 (en) 1989-09-20 1989-11-08 Wyeth John & Brother Ltd New method of treatment and heterocyclic compounds used therein
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) * 1990-11-27 1992-06-25 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
WO1992014443A1 (en) 1991-02-20 1992-09-03 Warner-Lambert Company Microsphere-in-oil emulsion
DK204791D0 (da) 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
RU94046105A (ru) * 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
GB9308430D0 (en) 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5792796A (en) 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
DK0804182T3 (da) 1994-07-27 2002-09-09 Warner Lambert Co Anvendelse af gabapentin ved behandling af angst og panik
GB9420784D0 (en) 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
AU4437896A (en) 1995-01-12 1996-07-31 Glaxo Group Limited Piperidine derivatives having tachykinin antagonist activity
CN1087290C (zh) 1995-02-28 2002-07-10 H·隆德贝克有限公司 4－氨基四氢苯并异噁唑或异噻唑化合物
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US5616793A (en) 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
ATE218135T1 (de) 1996-02-07 2002-06-15 Warner Lambert Co Zyklischaminosäure als pharmazeutische mittel
EA001214B1 (ru) 1996-03-14 2000-12-25 Варнер-Ламберт Компани Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества
JP2000506861A (ja) 1996-03-14 2000-06-06 ワーナー―ランバート・コンパニー 医薬としての新規な置換環状アミノ酸
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
WO1997049393A1 (en) 1996-06-26 1997-12-31 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
BR9812162A (pt) 1997-09-08 2000-07-18 Warner Lambert Co Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
KR20010033154A (ko) 1997-12-16 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 제약물로서의 신규한 아민
CU23051A3 (es) 1998-05-15 2005-06-24 Warner Lambert Co Composiciones solidas que contienen derivados de acido gamma-aminobutirico y procesos para prepararlas.
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6680343B1 (en) 1998-07-09 2004-01-20 Warner-Lambert Comapny Treatment of renal colic with GABA analogs
AU772156B2 (en) 1998-07-09 2004-04-08 Warner-Lambert Company Compositions comprising GABA analogs and caffeine
US20030045500A1 (en) 1998-07-09 2003-03-06 Leslie Magnus Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
BR9911887A (pt) 1998-07-09 2001-03-27 Warner Lambert Co Método para o tratamento da insÈnia
DK1121114T3 (da) 1998-10-16 2007-04-10 Warner Lambert Co Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser
CA2359485A1 (en) 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en) 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
IL145736A0 (en) 1999-04-09 2002-07-25 Warner Lambert Co Combinations of gaba analogs and tricyclic compounds to treat depression
WO2000073300A1 (en) 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
US6642398B2 (en) 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
AU5753900A (en) 1999-07-02 2001-01-22 Warner-Lambert Company A synergistic combination: gabapentin and pregabalin
US7030119B1 (en) 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
CA2384911C (en) 1999-09-16 2008-07-22 Warner-Lambert Company Method for the screening of .alpha.2. delta.-1 subunit binding ligands
AP2002002501A0 (en) 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
CN1210253C (zh) 2000-01-27 2005-07-13 沃尼尔·朗伯公司 不对称合成(s)－(+)－3－(氨甲基)－5－甲基己酸
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US7067262B2 (en) 2000-05-16 2006-06-27 Warner Lambert Company Llc Cell line for the expression of an α2δ2 calcium channel subunit and methods of use
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
CA2356829A1 (en) 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1337272A2 (en) 2000-11-30 2003-08-27 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
WO2002043762A2 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
ES2236134T3 (es) 2000-12-13 2005-07-16 Warner-Lambert Company Llc Ligandos bisfosfolanos p-quirales y sus complejos con metales de transicion.
US20040002543A1 (en) 2001-02-16 2004-01-01 Leslie Magnus Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
ATE297902T1 (de) 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
MXPA02001147A (es) 2001-03-19 2004-04-21 Warner Lambert Co Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica.
SK11852003A3 (sk) 2001-03-30 2004-07-07 Pfizer Products Inc. Derivát pyridazinónu ako inhibítor aldózreduktázy a farmaceutický prostriedok, ktorý ho obsahuje
EP1247809A3 (en) 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US7022678B2 (en) 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
CZ20032764A3 (cs) 2001-04-19 2004-04-14 Warner-Lambert Company Fúzní bicyklické nebo tricyklické aminokyseliny
RS87203A (en) 2001-05-25 2006-10-27 Warner-Lambert Company Liquid pharmaceutical composition
US20030045449A1 (en) 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
CN1625393A (zh) 2002-01-31 2005-06-08 沃纳-兰伯特公司 治疗耳鸣的α2δ配体
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20030225149A1 (en) 2002-04-30 2003-12-04 Blazecka Peter G. Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
JP2005534678A (ja) 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
CA2491994C (en) 2002-07-08 2013-11-05 Pfizer Products Inc. Modulators of the glucocorticoid receptor
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en) 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en) 2002-08-29 2006-07-04 Warner Lambert Company Llc Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7659305B2 (en) 2002-10-31 2010-02-09 Pfizer Inc. Therapeutic proline derivatives
JP2006510661A (ja) 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
JP2006511604A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 線維筋痛症及び関連する他の障害の治療のためのプレガバリン及びその誘導体
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
EP1633400A2 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2004108708A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
WO2005002585A1 (en) 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
AP2184A (en) 2003-09-03 2010-12-02 Pfizer Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
CN1878546A (zh) 2003-09-12 2006-12-13 沃纳-兰伯特公司 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
JP2007506729A (ja) 2003-09-25 2007-03-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー α２δタンパク質に親和性を有するアミノ酸のプロドラッグ
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1543831A1 (en) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
JP2007537151A (ja) 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
BRPI0508615A (pt) 2004-03-12 2007-07-31 Warner Lambert Co lingandos de bisfosfina c1-simétrica e seu emprego na sìntese assimétrica de pregabalina
CA2561488A1 (en) 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
BRPI0508998A (pt) 2004-04-01 2007-09-04 Warner Lambert Co preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica
DE602005011784D1 (de) 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
UA82292C2 (uk) 2004-04-14 2008-03-25 Пфайзер Продактс Инк. Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
MXPA06012172A (es) 2004-04-20 2007-01-17 Pfizer Prod Inc Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4.
JP2007533725A (ja) 2004-04-20 2007-11-22 ファイザー・インク Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
EA200801608A1 (ru) 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
GEP20104895B (en) 2004-06-21 2010-02-25 Warner Lambert Co Preparation of pregabalin and related compounds
MXPA06014022A (es) 2004-06-29 2007-02-08 Pfizer Prod Inc Prcedimientos para preparar inhibidores de p2x7.
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en) 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
GB0419849D0 (en) 2004-09-07 2004-10-13 Pfizer Ltd Pharmaceutical combination
BRPI0517925A (pt) 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
CN101087771A (zh) 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
US7122683B2 (en) 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
DK1828182T3 (da) 2004-11-29 2010-05-10 Warner Lambert Co Terapeutiske pyrazol[3,4-B]pyridiner og indazoler
MX2007010139A (es) 2005-02-22 2007-09-27 Pfizer Derivados de oxiindol como agonista del receptor 5ht4.
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
EP1858865B1 (en) 2005-03-10 2009-09-16 Pfizer Inc. Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds
EA200701745A1 (ru) 2005-03-17 2008-06-30 Пфайзер, Инк. Циклопропанкарбоксамидные производные
EP1874732A1 (en) 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
KR100925900B1 (ko) 2005-04-28 2009-11-09 화이자 리미티드 아미노산 유도체
CN101180045A (zh) 2005-05-20 2008-05-14 辉瑞有限公司 非甾类抗炎药物与α-2-δ配体的协同组合
WO2006129164A1 (en) 2005-05-31 2006-12-07 Pfizer Japan Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
NL2000284C2 (nl) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
PL1948615T3 (pl) 2005-11-08 2012-04-30 Pfizer Ltd Pochodne pirazolu przydatne w leczeniu chorób ginekologicznych
AU2006321349A1 (en) 2005-12-02 2007-06-07 Pfizer Limited Spirocyclic quinazoline derivatives as PDE7 inhibitors
CA2530904C (en) 2005-12-20 2013-10-08 John Marino Pharmaceutical agents for the treatment of pain associated with spinal cord injury
BRPI0708671A2 (pt) 2006-03-06 2011-06-07 Pfizer Prod Inc ligantes alfa-2-delta para sono não restaurador
GB0700786D0 (en) 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
MY153057A (en) 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
WO2008132589A1 (en) 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin

Also Published As

Publication number Publication date
NO990279D0 (no) 1999-01-22
ES2200184T9 (es) 2015-03-20
HUP9904361A3 (en) 2000-11-28
SI0934061T1 (en) 2003-10-31
IL126999A (en) 2002-03-10
CN1094757C (zh) 2002-11-27
EP0934061B1 (en) 2003-05-28
CA2255652C (en) 2004-07-13
US6001876A (en) 1999-12-14
KR100491282B1 (ko) 2005-05-24
AU3602497A (en) 1998-02-10
DE69722426T3 (de) 2015-05-07
NZ332762A (en) 2000-09-29
HK1021134A1 (en) 2000-06-02
CU22850A3 (es) 2003-04-28
USRE41920E1 (en) 2010-11-09
HU228426B1 (hu) 2013-03-28
HUP9904361A2 (hu) 2000-05-28
HRP970387A2 (en) 1998-10-31
CN1223574A (zh) 1999-07-21
JP2000515149A (ja) 2000-11-14
EP0934061A1 (en) 1999-08-11
DE69722426D1 (de) 2003-07-03
BR9710536A (pt) 1999-08-17
DK0934061T3 (da) 2003-09-22
DE69722426T2 (de) 2004-04-08
NO990279L (no) 1999-01-22
AU714980B2 (en) 2000-01-13
DK0934061T6 (en) 2015-01-26
KR20000068015A (ko) 2000-11-25
ZA976562B (en) 1998-02-03
ATE241351T1 (de) 2003-06-15
PL331325A1 (en) 1999-07-05
CA2255652A1 (en) 1998-01-29
JP3693258B2 (ja) 2005-09-07
IL126999A0 (en) 1999-09-22
HUS1300046I1 (hu) 2016-08-29
NO2008018I2 (no) 2010-06-28
PL189872B1 (pl) 2005-10-31
WO1998003167A1 (en) 1998-01-29
ES2200184T7 (es) 2015-02-10
ES2200184T3 (es) 2004-03-01
EP0934061B3 (en) 2015-01-21
NO2008018I1 (no) 2008-12-15
NO325822B1 (no) 2008-07-21

Similar Documents

Publication Publication Date Title
BR9710536A (pt) Isobutilgaba e seus derivados para o tratamento da dor
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR9911887A (pt) Método para o tratamento da insÈnia
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
FI950909A0 (fi) Rasvahappojohdannaisia
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
BR9908358A (pt) Preparação para tratamento da disfunção erétil
BR9708037A (pt) Método para o tratamento de abuso de substância
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
UA7951A (uk) Спосіб сочетаної вакуум-лазерної терапії